The impact of pathogen reduction on ABO isoagglutinin titers in apheresis platelets

IF 1.8 Q3 HEMATOLOGY
Mikayel Yeghiazaryan , Yembur Ahmad , Jessie Singer , Vaanush Nazaryan , Craig Fletcher , Yamac Akgun
{"title":"The impact of pathogen reduction on ABO isoagglutinin titers in apheresis platelets","authors":"Mikayel Yeghiazaryan ,&nbsp;Yembur Ahmad ,&nbsp;Jessie Singer ,&nbsp;Vaanush Nazaryan ,&nbsp;Craig Fletcher ,&nbsp;Yamac Akgun","doi":"10.1016/j.htct.2025.103840","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Platelet transfusions are a cornerstone of modern medical care, used across various clinical contexts. Ensuring the compatibility of blood products, especially regarding ABO isoagglutinins, is critical to minimize adverse reactions. Pathogen reduction technologies have been widely adopted to enhance the safety of blood products, however, the impact of such treatments on ABO isoagglutinin titers in platelet products remains unclear.</div></div><div><h3>Methods</h3><div>This study analyzed 60 apheresis platelet donations, including type O, A, and B donors, using the INTERCEPT® Blood System for pathogen reduction. Samples were collected both from donor whole blood at the time of apheresis (Retention) and from the final pathogen-reduced platelet product after it had passed through the compound adsorption device (Post-CAD). ABO isoagglutinin titers, including both IgM and IgG classes, were measured using solid-phase technology on the NEO Iris platform.</div></div><div><h3>Results</h3><div>This study found a significant reduction in IgM isoagglutinin titers in Post-CAD samples, with 99 % of Retention titers being greater than or equal to their Post-CAD counterparts. IgG titers exhibited more variability, with 9 % of Post-CAD samples displaying higher titers than Retention samples. Statistical analysis confirmed differences between Retention and Post-CAD samples for both IgM and IgG titers, with p-values &lt;0.05 in most comparisons.</div></div><div><h3>Conclusion</h3><div>Pathogen reduction using the INTERCEPT® Blood System effectively reduces ABO isoagglutinin titers in apheresis platelets, potentially lowering the risk of hemolytic transfusion reactions. This reduction is beneficial for safer out-of-group platelet transfusions, especially in vulnerable populations such as pediatric patients. These findings support the continued use of pathogen-reduced platelets in transfusion medicine to enhance both safety and availability of blood products.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103840"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology, Transfusion and Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2531137925001087","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Platelet transfusions are a cornerstone of modern medical care, used across various clinical contexts. Ensuring the compatibility of blood products, especially regarding ABO isoagglutinins, is critical to minimize adverse reactions. Pathogen reduction technologies have been widely adopted to enhance the safety of blood products, however, the impact of such treatments on ABO isoagglutinin titers in platelet products remains unclear.

Methods

This study analyzed 60 apheresis platelet donations, including type O, A, and B donors, using the INTERCEPT® Blood System for pathogen reduction. Samples were collected both from donor whole blood at the time of apheresis (Retention) and from the final pathogen-reduced platelet product after it had passed through the compound adsorption device (Post-CAD). ABO isoagglutinin titers, including both IgM and IgG classes, were measured using solid-phase technology on the NEO Iris platform.

Results

This study found a significant reduction in IgM isoagglutinin titers in Post-CAD samples, with 99 % of Retention titers being greater than or equal to their Post-CAD counterparts. IgG titers exhibited more variability, with 9 % of Post-CAD samples displaying higher titers than Retention samples. Statistical analysis confirmed differences between Retention and Post-CAD samples for both IgM and IgG titers, with p-values <0.05 in most comparisons.

Conclusion

Pathogen reduction using the INTERCEPT® Blood System effectively reduces ABO isoagglutinin titers in apheresis platelets, potentially lowering the risk of hemolytic transfusion reactions. This reduction is beneficial for safer out-of-group platelet transfusions, especially in vulnerable populations such as pediatric patients. These findings support the continued use of pathogen-reduced platelets in transfusion medicine to enhance both safety and availability of blood products.
病原减少对单采血小板ABO异凝集素滴度的影响
血小板输注是现代医疗保健的基石,用于各种临床情况。确保血液制品的相容性,特别是ABO异凝集素,对于减少不良反应至关重要。病原减少技术已被广泛采用,以提高血液制品的安全性,然而,这种处理对血小板产品ABO异凝集素滴度的影响尚不清楚。方法本研究使用INTERCEPT®血液系统分析60例单采血小板捐献,包括O型、A型和B型,用于减少病原体。样品采集于供者全血分离时(Retention)和最终病原体还原血小板产物通过复合吸附装置后(Post-CAD)。在NEO Iris平台上使用固相技术测量ABO异凝集素滴度,包括IgM和IgG类。结果本研究发现,cad后样品中IgM异凝集素滴度显著降低,99%的保留滴度大于或等于cad后样品的滴度。IgG滴度表现出更多的可变性,9%的cad后样品的滴度高于保留样品。统计分析证实了保留和cad后样品中IgM和IgG滴度的差异,大多数比较的p值为<;0.05。结论使用INTERCEPT®血液系统减少病原体可有效降低单采血小板ABO异凝集素滴度,潜在降低溶血性输血反应的风险。这种减少有利于更安全的组外血小板输注,特别是在儿科患者等弱势人群中。这些发现支持在输血医学中继续使用病原体减少的血小板,以提高血液制品的安全性和可得性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.40
自引率
4.80%
发文量
1419
审稿时长
30 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信